Impact of HER2-low and HER2-zero status on outcomes: A multicenter propensity-score matched study

被引：0
|
作者：
Cha, C. D. [1 ]
Kim, K. E. [2 ]
Kim, J. [3 ]
Um, E. [4 ]
Choi, N. [5 ]
Lee, J. [2 ]
Gwak, G. [3 ]
Kim, J. I. [4 ]
Chung, M. S. [1 ]
机构：
[1] Hanyang Univ, Coll Med, Surg, Seoul, South Korea
[2] Inje Univ, Coll Med, Surg, Haeundae Paik Hosp, Busan, South Korea
[3] Inje Univ, Sanggye Paik Hosp, Sch Med, Surg, Seoul, South Korea
[4] Inje Univ, Ilsan Paik Hosp, Ilsan, South Korea
[5] Hanyang Univ, Med Res Collaborating Ctr, Seoul, South Korea
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.104089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P248
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer
    Reinert, Tomas
    Sartori, Guilherme Parisotto
    Souza, Alessandra A. B.
    Pellegrini, Rodrigo
    Rosa, Mahira L.
    Rossatto, Nathalia
    Coelho, Guilherme P.
    Litvin, Isnard E.
    Zerwes, Felipe
    Millen, Eduardo
    Cavalcante, Francisco P.
    Frasson, Antonio L.
    Graudenz, Marcia S.
    Barrios, Carlos H.
    CANCER RESEARCH, 2021, 81 (04)
  • [22] Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
    Shi, Zhendong
    Liu, Yingxue
    Fang, Xuan
    Liu, Xu
    Meng, Jie
    Zhang, Jin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [23] Clinical characteristics, tumor-infiltrating lymphocytes, and prognosis in HER2-low breast cancer: A comparison study with HER2-zero and HER2-positive disease
    Lu, Yujie
    Tong, Yiwei
    Fei, Xiaochun
    Chen, Xiaosong
    Shen, Kunwei
    CANCER MEDICINE, 2023, 12 (15): : 16264 - 16278
  • [24] Event-free survival in HER2-low vs HER2-zero breast cancer patients submitted to neoadjuvant chemotherapy
    Sartori, Guilherme
    Ramalho, Susana
    da Silva, Leonardo Roberto
    Reinert, Tomas
    Da Rosa, Mahira Lopes
    Tavares, Grazielle Morais
    Vasconcelos, Vivian
    Mantovani, Higor
    Cabello, Ana Elisa Ribeiro Da Silva
    Coelho, Guilherme
    Mandelli, Jovana
    Zaffaroni, Facundo
    Cabello, Cesar
    Barrios, Carlos
    Graudenz, Marcia Silveira
    CANCER RESEARCH, 2024, 84 (09)
  • [25] Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis
    Li, Chengxin
    Yuan, Qianqian
    Deng, Tong
    Xu, Gaoran
    Hou, Jinxuan
    Zheng, Lewei
    Wu, Gaosong
    BREAST CANCER, 2023, 30 (06) : 965 - 975
  • [26] Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer
    Zhan, Ting
    Dai, Jiankun
    Li, Yan
    EUROPEAN JOURNAL OF RADIOLOGY, 2024, 177
  • [27] Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis
    Chengxin Li
    Qianqian Yuan
    Tong Deng
    Gaoran Xu
    Jinxuan Hou
    Lewei Zheng
    Gaosong Wu
    Breast Cancer, 2023, 30 : 965 - 975
  • [28] Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer
    Liu, Jing-Jing
    Zhang, Yi
    Zhang, Shi-Chao
    Liu, Xu
    Wang, Shu-Nan
    Liu, Xin-Yu
    Zhang, Jin
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [29] Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy
    Kang, Sora
    Lee, So H.
    Lee, Hee J.
    Jeong, Hyehyun
    Jeong, Jae H.
    Kim, Jeong E.
    Ahn, Jin-Hee
    Jung, Kyung H.
    Gong, Gyungyub
    Kim, Hak H.
    Lee, Saebyeol
    Lee, Jongwon
    Kim, Sung-Bae
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 30 - 40
  • [30] Pathologic complete response, long-term outcomes, and recurrence patterns in HER2-low vs HER2-zero breast cancer after neoadjuvant chemotherapy
    Kang, S.
    Lee, S. H.
    Lee, H. J.
    Jeong, H.
    Jeong, J-H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Gong, G.
    Kim, H. H.
    Lee, S.
    Lee, J.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S624 - S624
12345